EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Nephrology News Source Type: news
More News: Cardiology | Chronic Kidney Disease | Diabetes | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors | Urology & Nephrology